Quanterix Corporation - QTRX STOCK NEWS

Quanterix Corporation (Nasdaq: QTRX) has announced the pricing of its public offering of 3,571,428 shares of common stock at $70.00 per share, aiming for gross proceeds of approximately $250 million. The offering, which is expected to close on or about February 8, 2021, includes an option for underwriters to purchase an additional 535,714 shares. The offering is filed under a previously effective shelf registration statement. Goldman Sachs, SVB Leerink, and Cowen are the joint bookrunning managers for this offering.

Quanterix Corporation (Nasdaq: QTRX) has launched an underwritten public offering of $200 million of its common stock, with an option for underwriters to purchase an additional 15%. This offering is aimed at supporting its digitization of biomarker analysis, playing a significant role in precision health. The offering will occur under an existing shelf registration statement. Quanterix is working with Goldman Sachs, SVB Leerink, and Cowen as bookrunning managers. Market conditions may affect the completion and final terms of the offering.

Quanterix Corporation (NASDAQ: QTRX) announced that CEO Kevin Hrusovsky will present at the PMWC 2021 COVID-19 Conference from Jan. 25-27, 2021. Hrusovsky will join a panel discussing COVID-19 tracking methodologies on Jan. 25 at 9:50 a.m. PST. Quanterix is advancing precision health through its digital health solution, Simoa, which enhances early disease detection and treatment methods across various therapeutic areas, including oncology and neurology. Founded in 2007, the company is based in Billerica, Massachusetts.

Quanterix (NASDAQ: QTRX) has disclosed operational and preliminary financial results for Q4 and FY 2020. The company thrived despite pandemic challenges, pivoting to develop COVID-19 testing solutions, including an $18.2M NIH contract. Key operational milestones include FDA Emergency Use Authorizations for its antigen tests and significant advancements in neurology biomarkers. Q4 GAAP revenue is projected at $24-26 million, with non-GAAP revenue expected to rise by 32%, totaling $20-22 million. The company raised $97.6 million through a follow-on offering, enhancing its financial position for future growth.

Quanterix Corporation (NASDAQ:QTRX) received FDA Emergency Use Authorization for its Simoa® SARS-CoV-2 N Protein Antigen Test, which detects the SARS-CoV-2 virus nucleocapsid protein. The test shows 97.7% sensitivity and 100% specificity within 14 days post-symptom onset. Intended for nasopharyngeal samples, Quanterix plans to expand to other sample types. This initiative is part of the NIH-funded RADx program to enhance SARS-CoV-2 testing capacity in the U.S. Additionally, Quanterix launched the SARS-CoV-2 N Protein Antigen Advantage Assay for research use.

Quanterix Corporation (NASDAQ: QTRX) announced that its CEO, Kevin Hrusovsky, will present on the company's growth at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 3:40 p.m. EST. This marks Hrusovsky's fifth consecutive year presenting at this conference. The live webcast will be accessible for attendees and the public. Quanterix focuses on advancing precision health through digitizing biomarker analysis, aiming for earlier disease detection and improved treatment methodologies across multiple therapeutic areas, including oncology and neurology.

Quanterix Corporation (NASDAQ: QTRX) announced that the FDA granted Emergency Use Authorization (EUA) for its Simoa® Semi-Quantitative SARS-CoV-2 IgG Antibody Test, which operates on the Simoa HD-X Analyzer. This test measures the antibody response to the coronavirus spike protein and is vital for assessing immunity from COVID-19 vaccines and previous infections. Clinical studies indicate a sensitivity of 100% and specificity of 99.2%, supporting its reliability. Quanterix aims to aid COVID-19 immunology studies and enhance disease detection.

Quanterix Corporation (NASDAQ: QTRX) has appointed William Geist as Chief Operating Officer, effective November 16, 2020. Geist, with over 25 years of experience, previously led major business units at Thermo Fisher Scientific. His focus will be on enhancing Quanterix’s ultrasensitive Simoa® technology and expanding its applications across various therapeutic areas, including COVID-19, Immunology, and Oncology. This strategic hire aims to leverage his operational expertise to drive growth and innovation within the company, reinforcing Quanterix’s position in precision health.

Quanterix Corporation (NASDAQ: QTRX) announced that Chairman and CEO, Kevin Hrusovsky, will participate in a virtual fireside chat at the Canaccord Medical Technologies and Diagnostics Forum on November 19 at 10:30 a.m. EST. This engagement will include one-on-one and group meetings with institutional investors. A live webcast will be available on the Quanterix investor relations page, with replays accessible for 90 days thereafter. Quanterix is focused on advancing precision health through its digital health solution, Simoa.